Vagulienė N. THE PEMBREIZH MULTICENTER REAL-LIFE COHORT STUDY: FIRST LINE PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER PATIENTS WITH PD-L1 ≥50% [Internet]. PIA 2020 Sep.;4(2):164-167.[cited 2026 Nov. 12 ] Available from: https://ejournals.vitaelitera.lt/index.php/PIA/article/view/119